Argent Biopharma Limited Date of AGM & Closing Date of Director Nominations

RNS Number : 5923F

Argent Biopharma Limited

25 September 2024

 

 

25 September 2024

 

Argent BioPharma Ltd.

(Argent BioPharma or the Company)

 

Date of AGM and Closing Date for Director Nominations

 

Argent BioPharma, an innovative multidisciplinary drug discovery company within the biopharmaceutical sector, advises that in accordance with ASX Listing Rule 3.13.1, that the Company's Annual General Meeting is planned to be held on Thursday, 28 November 2024.

 

The closing date for receipt of nominations for persons wishing to be considered for election as a director is, 10 October 2024. Any nominations must be received at the Company's registered office no later than 5.00pm (WST) on 10 October 2024.

 

-Ends-

 

Authorised for release by the Company Secretary, for further information please contact:

 

Argent BioPharma Roby Zomer CEO & Managing Director [phone] [e-mail]

Argent BioPharma Rowan Harland Company Secretary [phone] [e-mail]

About Argent BioPharma

 

Argent BioPharma Limited (the "Company") (ASX: RGT; LSE: RGT; OTCQB: RGTLF) an innovative multidisciplinary drug development Company within the biopharmaceutical sector.  The Company focuses on multidisciplinary methods with Nanotechnology, developing multi-target therapies for comprehensive disease management, especially concerning the central nervous system ("CNS") and Immunology treatments.

 

Follow us through our social media channels:

LinkedIn: Argent BioPharma

Twitter: @ArgentBioPharma

Facebook: Argent BioPharma

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

NOALAMFTMTITMPI